Published in J Toxicol Environ Health on May 01, 1977
A case-control comparison of the results of renal transplantation from heart-beating and non-heart-beating donors. Transplantation (2001) 1.52
Platelet-activating factor antagonists. Annu Rev Pharmacol Toxicol (1987) 1.36
Effect of glucagon on hepatic malonyl coenzyme A concentration and on lipid synthesis. J Biol Chem (1977) 1.28
An algorithm for the management of bile leak following laparoscopic cholecystectomy. Ann R Coll Surg Engl (2007) 1.20
Inhibition of PAF-induced systemic responses in the rat, guinea pig, dog and primate by the receptor antagonist SRI 63-441. Thromb Haemost (1986) 1.09
Loperamide binding to opiate receptor sites of brain and myenteric plexus. J Pharmacol Exp Ther (1976) 1.06
32P analysis of DNA adducts in tissues of benzene-treated rats. Environ Health Perspect (1989) 1.05
Quantitation of in vivo platelet aggregation by the platelet aggregate ratio method. Thromb Res (1977) 1.04
Release of platelet-activating factor from ischemic-reperfused rabbit heart. Am J Physiol (1989) 1.01
Paths of carbon in gluconeogenesis and lipogenesis. VII. The synthesis of precursors for gluconeogenesis from pyruvate and bicarbonate by rat kidney mitochondria. J Biol Chem (1967) 1.01
Effect of platelet activating factor on endothelial permeability to plasma macromolecules. Immunopharmacology (1984) 0.97
The binding of [3H]diazepam to rat brain homogenates. J Pharmacol Exp Ther (1978) 0.93
Oxidation and phosphorylation in live mitochondria from alloxan and steptozotocin diabetic rats. Proc Soc Exp Biol Med (1971) 0.92
Inhibition and reversal of endotoxin-, aggregated IgG- and paf-induced hypotension in the rat by SRI 63-072, a paf receptor antagonist. Immunopharmacology (1986) 0.91
Toxicity and biochemical mechanisms of ozone. Environ Res (1987) 0.89
A method for in vitro culture of rat Zymbal gland: use in mechanistic studies of benzene carcinogenesis in combination with 32P-postlabeling. Environ Health Perspect (1989) 0.88
Metabolic fate of 1,3-butanediol in the rat: conversion to -hydroxybutyrate. J Nutr (1971) 0.88
Carnitine-14C metabolism in choline-deficient, alloxan-diabetic choline-deficient and insulin-treated rats. Metabolism (1971) 0.88
Current toxicological information as the basis for sulfur oxide standards. Environ Health Perspect (1983) 0.86
Interaction of loperamide with [3H]naloxone binding sites in guinea pig brain and myenteric plexus. Mol Pharmacol (1977) 0.85
In vitro and in vivo pharmacological profiles of the PAF receptor antagonist SRI 63-675. Thromb Haemost (1987) 0.85
Biological effects of the orally active platelet activating factor receptor antagonist SDZ 64-412. J Pharmacol Exp Ther (1988) 0.85
Effect of sub-acute administration of clofibrate on the oxidation of fatty acids by liver mitochondria. Biochem Pharmacol (1977) 0.85
Utilization of 1,3-butanediol and nonspecific nitrogen in human adults. J Nutr (1973) 0.85
An automated myeloperoxidase assay. Clin Chem (1990) 0.84
Vascular responses of platelet-activating factor in the Cebus apella primate and inhibitory profiles of antagonists SRI 63-072 and SRI 63-119. Immunopharmacology (1986) 0.84
In vitro and in vivo percutaneous absorption of benzo[a]pyrene from petroleum crude-fortified soil in the rat. Bull Environ Contam Toxicol (1989) 0.84
Evaluation of platelet-inhibiting drugs in models of atherosclerosis. Annu Rev Pharmacol Toxicol (1982) 0.84
pH effects on oxidative phosphorylation of rat liver mitochondria. Am J Physiol (1972) 0.82
Suppression of rat carotid lesion development by the calcium channel blocker PN 200-110. Am J Pathol (1986) 0.82
Metabolism of carnitine in cold-acclimated rats. Can J Biochem (1965) 0.82
Regulation of gluconeogenesis and lipogenesis. Inhibition of pyruvate carboxylation in rat kidney mitochondria by malonate and malonyl CoA. Arch Biochem Biophys (1968) 0.81
Health effects of the alkylbenzenes. I. Toluene. Toxicol Ind Health (1988) 0.81
Metabolic control of enzymes in normal, diabetic, and diabetic insulin-treated rats utilizing 1,3 butanediol. Metabolism (1971) 0.81
Effects of clofibrate, in vitro, on mitochondrial respiration and oxidative phosphorylation. Biochem Pharmacol (1973) 0.81
SAR models for estimating the percutaneous absorption of polynuclear aromatic hydrocarbons. SAR QSAR Environ Res (1998) 0.80
Health effects of the alkylbenzenes. II. Xylenes. Toxicol Ind Health (1989) 0.80
Biological properties of the antagonist SRI 63-441 in the PAF and endotoxin models of hypotension in the rat and dog. Immunopharmacology (1987) 0.80
Fate of isotopic carbon in kidney mitochondria synthesizing precursors for glucose from pyruvate and bicarbonate. J Biol Chem (1968) 0.80
Metabolism, turnover time, half life, body pool of carnitine-14C in normal, alloxan diabetic and insulin treated rats. Life Sci (1969) 0.80
Lack of DNA adduct formation in mice treated with benzene. Mutat Res (1994) 0.80
Antiplatelet activity of hydralazine. Thromb Res (1979) 0.80
Evidence for distinct systemic extravasation effects of platelet activating factor, leukotrienes B4, C4, D4 and histamine in the guinea pig. Prostaglandins Leukot Med (1986) 0.80
Correlation of mutagenic and dermal carcinogenic activities of mineral oils with polycyclic aromatic compound content. Fundam Appl Toxicol (1988) 0.80
Evaluation of dose and route effects of platelet activating factor-induced extravasation in the guinea pig. Thromb Haemost (1984) 0.79
Oxidative phosphorylation and respiration by rat liver mitochondria from aspirin-treated rats. Biochem Pharmacol (1972) 0.79
Percutaneous and oral absorption of chlorinated paraffins in the rat. Toxicol Ind Health (1987) 0.78
Further studies concerning the effects of clofibrate on respiration and oxidative phosphorylation of rat liver mitochondria. Biochem Pharmacol (1974) 0.78
A report on methods to reduce, refine and replace animal testing in industrial toxicology laboratories. Cell Biol Toxicol (1989) 0.78
Developmental toxicity of dermally applied crude oils in rats. J Toxicol Environ Health (1997) 0.78
Increased vascular resistance by prostaglandins B 1 and B 2 in the isolated rat pancreas. Nat New Biol (1972) 0.78
Nutritional and metabolic studies in humans with 1,3-butanediol. Fed Proc (1975) 0.78
Release of platelet-activating factor from rabbit heart perfused in vitro by sera with transplantation alloantibodies. Transplantation (1987) 0.78
Changes in vascular resistance induced by prostaglandins E 2 and F 2 in the isolated rat pancreas. Arch Int Pharmacodyn Ther (1972) 0.78
Regulation of gluconeogenesis and lipogenesis. The regulation of mitochondrial pyruvate metabolism in guinea-pig liver synthesizing precursors for gluconeogenesis. Biochem J (1969) 0.78
Inhibition of pyruvate carboxylation by fluorocitrate in rat kidney mitochondria. J Biol Chem (1968) 0.78
Effect of thyroxine and 5,5-diphenyl-2-thiohydantoin on enzyme activities of rat liver and kidney. Endocrinology (1972) 0.78
Percutaneous absorption of benzo[a]pyrene in the rat: comparison of in vivo and in vitro results. Toxicol Ind Health (1986) 0.78
Percutaneous absorption of anthracene in the rat: comparison of in vivo and in vitro results. Toxicol Ind Health (1986) 0.78
DNA adduction by phenol, hydroquinone, or benzoquinone in vitro but not in vivo: nuclease P1-enhanced 32P-postlabeling of adducts as labeled nucleoside bisphosphates, dinucleotides and nucleoside monophosphates. Carcinogenesis (1990) 0.77
Inhibition by SRI 63-072 and SRI 63-119 of PAF-acether and immune complex effects in the guinea pig. Eur J Pharmacol (1987) 0.77
Thiamin deficiency: liver metabolite levels and redox and phosphorylation states in thiamin-deficient rats. J Nutr (1973) 0.77
Suppression of fibroblast proliferation in vitro and of myointimal hyperplasia in vivo by the triazolopyrimidine, Trapidil. Artery (1983) 0.77
Evaluation of the effect of a platelet activating factor antagonist on platelet activating factor and Ascaris antigen-induced airway responses in rhesus monkeys. J Lab Clin Med (1987) 0.77
Antiestrogenicity of clarified slurry oil and two crude oils in a human breast-cancer cell assay. J Toxicol Environ Health A (2001) 0.77
Redox and phosphorylation states and metabolite concentrations in frozen clamped livers of rats fed diets containing 1,3-butanediol and DL-carnitine. J Nutr (1972) 0.77
Evidence for a direct effect on vascular permeability of platelet-activating factor induced hemoconcentration in the guinea pig. Thromb Haemost (1985) 0.77
Brain metabolite concentrations and redox states in rats fed diets containing 1,3-butanediol and ethanol. Toxicol Appl Pharmacol (1974) 0.76
Pharmacokinetics and metabolism of benzene in Zymbal gland and other key target tissues after oral administration in rats. Environ Health Perspect (1989) 0.76
Effects of pirfenidone on vascular smooth muscle cell proliferation and intimal hyperplasia following arterial balloon injury. Transplant Proc (2001) 0.76
Benzene induces a dose-responsive increase in the frequency of micronucleated cells in rat Zymbal glands. Environ Health Perspect (1996) 0.76
Antidiarrheal and central nervous system activities of SC-27166 (2-[3 - 5 - methyl - 1, 3, 4 - oxadiazol - 2 - yl) - 3, 3 - diphenylpropyl] - 2 - azabicyclo [2.2.2]octane), a new antidiarrheal agent, resulting from binding to opiate receptor sites of brain and myenteric plexus. J Pharmacol Exp Ther (1977) 0.76
Use of a surrogate aerosol in a preliminary screening for the potential carcinogenicity of coal coated with No. 6 fuel oil. Am Ind Hyg Assoc J (1998) 0.76
Metabolite levels, redox states, and gluconeogenic enzyme activities in livers of rats fed diets containing 1,3-butanediol. J Environ Pathol Toxicol (1979) 0.76
Current status of benzene teratology: a brief review. J Environ Pathol Toxicol (1980) 0.76
Mode of action of aspirin. Effect of dietary aspirin on mitochondrial pyruvate metabolism in normal and thiamine-deficient rats. J Biol Chem (1971) 0.75
MTBE toxicity. Environ Health Perspect (1996) 0.75
Prospective study of routine contrast radiology after total gastrectomy (Br J Surg 2004; 91: 1015-1019). Br J Surg (2004) 0.75
Misclassification of carcinogenic methyl tertiary butyl ether (MTBE) by the National Toxicology Program Board: smokescreen in, science out? Arch Environ Health (2000) 0.75
Cancer risk from exposure to motor fuel containing MTBE: "reasonably anticipated to be a human carcinogen". Int J Occup Environ Health (2000) 0.75
Platelets and atherosclerosis. Prog Drug Res (1985) 0.75
Metabolism cage for carbon dioxide trapping studies. J Toxicol Environ Health (1977) 0.75
In vivo effect of suloctidil as an antiplatelet agent. Thromb Haemost (1979) 0.75
Effects of SC-26096(2-methyl-3-oxo-2azabicyclo(2.2.2.)octan-6-exo-yl 5-(4-biphenylyl)-3-methyl valerate), a new hypolipidemic agent, on mitochondrial respiration and oxidative phosphorylation. Biochem Pharmacol (1974) 0.75
Stimulation of DOPA14C incorporation into melanoma tissue by chlorpromazine and reserpine. Toxicol Appl Pharmacol (1970) 0.75
Current status of drugs used to treat hyperlipoproteinemias. Drug Ther (1982) 0.75
Hazardous pollutant: gasoline containing methyl tertiary-butyl ether (MTBE) Int J Occup Environ Health (1999) 0.75
Amniotic bands. A case report. S Afr Med J (1981) 0.75
The biological properties of aspartame. V. Effects on a variety of physiological parameters related to inflammation and metabolism. J Environ Pathol Toxicol (1981) 0.75
Influence of 1,3-butanediol on blood glucose concentration and pancreatic insulin content of streptozotocin-diabetic rats. Fed Proc (1975) 0.75
The retired breeder rat as a new model for antiplatelet drug discovery. Lab Anim Sci (1977) 0.75
Synthesis and biological activities of arachidonic and alpha- and beta-alkyl-substituted arachidonic acid derivatives. Adv Prostaglandin Thromboxane Res (1980) 0.75